Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:IKT NASDAQ:JANX NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.42+0.9%$5.63$1.85▼$7.18$888.03M1.222.12 million shs2.14 million shsIKTInhibikase Therapeutics$1.75-1.1%$1.78$1.33▼$2.26$231.06M0.96700,814 shs306,263 shsJANXJanux Therapeutics$14.59-1.0%$14.51$12.12▼$35.34$889.76M2.58934,260 shs1.05 million shsPHARPharming Group$12.99-4.9%$15.38$9.54▼$21.34$917.42M0.0415,739 shs21,756 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon0.00%+2.07%-7.67%-3.21%+167.00%IKTInhibikase Therapeutics0.00%+3.55%-7.41%-14.63%+174,999,900.00%JANXJanux Therapeutics0.00%+0.48%+1.53%+7.20%-38.44%PHARPharming Group0.00%+3.10%-21.77%-20.31%+26.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.42+0.9%$5.63$1.85▼$7.18$888.03M1.222.12 million shs2.14 million shsIKTInhibikase Therapeutics$1.75-1.1%$1.78$1.33▼$2.26$231.06M0.96700,814 shs306,263 shsJANXJanux Therapeutics$14.59-1.0%$14.51$12.12▼$35.34$889.76M2.58934,260 shs1.05 million shsPHARPharming Group$12.99-4.9%$15.38$9.54▼$21.34$917.42M0.0415,739 shs21,756 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon0.00%+2.07%-7.67%-3.21%+167.00%IKTInhibikase Therapeutics0.00%+3.55%-7.41%-14.63%+174,999,900.00%JANXJanux Therapeutics0.00%+0.48%+1.53%+7.20%-38.44%PHARPharming Group0.00%+3.10%-21.77%-20.31%+26.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.43Hold$16.00195.20% UpsideIKTInhibikase Therapeutics 3.13Buy$5.50214.29% UpsideJANXJanux Therapeutics 2.60Moderate Buy$45.85214.23% UpsidePHARPharming Group 2.40Hold$38.33195.10% UpsideCurrent Analyst Ratings BreakdownLatest IKT, PHAR, JANX, and ANNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/11/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/11/2026JANXJanux Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$22.005/8/2026JANXJanux Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $26.005/8/2026JANXJanux Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$45.00 ➝ $36.005/8/2026JANXJanux Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$68.00 ➝ $58.005/4/2026JANXJanux Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/28/2026JANXJanux Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $28.004/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/22/2026JANXJanux Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 5/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$1.25 per shareN/AIKTInhibikase Therapeutics$260K888.66N/AN/A$1.27 per share1.38JANXJanux Therapeutics$10M88.97N/AN/A$15.44 per share0.94PHARPharming Group$376.13M2.44$0.20 per share64.77$3.81 per share3.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%8/13/2026 (Estimated)IKTInhibikase Therapeutics-$48.26M-$0.43N/AN/AN/AN/A-41.31%-38.98%N/AJANXJanux Therapeutics-$113.62M-$1.84N/AN/AN/AN/A-12.93%-12.23%8/6/2026 (Estimated)PHARPharming Group$2.85M$0.1681.1919.98N/A3.30%4.64%2.55%7/30/2026 (Estimated)Latest IKT, PHAR, JANX, and ANNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026IKTInhibikase Therapeutics-$0.10-$0.10N/A-$0.10N/AN/A5/7/2026Q1 2026ANNXAnnexon-$0.30-$0.23+$0.07-$0.23$5.50 millionN/A5/7/2026Q1 2026JANXJanux Therapeutics-$0.5202-$0.39+$0.1302-$0.39$4.36 million$3.73 million5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million3/30/2026Q4 2025ANNXAnnexon-$0.32-$0.28+$0.04-$0.28$3.25 millionN/A3/26/2026Q4 2025IKTInhibikase Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A6.356.35IKTInhibikase TherapeuticsN/A30.1430.14JANXJanux TherapeuticsN/A17.0117.01PHARPharming Group0.352.632.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AIKTInhibikase Therapeutics3.81%JANXJanux Therapeutics75.39%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%IKTInhibikase Therapeutics7.30%JANXJanux Therapeutics7.90%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60163.84 million144.40 millionOptionableIKTInhibikase Therapeutics6132.03 million122.40 millionN/AJANXJanux Therapeutics3060.98 million56.17 millionOptionablePHARPharming Group28070.62 million69.16 millionNot OptionableIKT, PHAR, JANX, and ANNX HeadlinesRecent News About These CompaniesPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by AnalystsMay 30 at 2:09 AM | americanbankingnews.comPharming Group N.V.: Pharming Group announces results of 2026 Annual General Meeting of ShareholdersMay 28 at 12:34 AM | finanznachrichten.dePharming Group announces results of 2026 Annual General Meeting of ShareholdersMay 28 at 12:34 AM | manilatimes.netMPharming Group N.V. (PHAR) Shareholder/Analyst Call - SlideshowMay 28 at 12:32 PM | seekingalpha.comPharming’s Joenja receives European marketing authorization for the treatment of activated PI3K delta syndromeMay 26, 2026 | pharmabiz.comPEuropean Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European UnionMay 22, 2026 | markets.businessinsider.comPharming Group N.V. Recorded A 21% Miss On Revenue: Analysts Are Revisiting Their ModelsMay 10, 2026 | finance.yahoo.comPharming Group (PHAR) Gets a Buy from Canaccord GenuityMay 9, 2026 | theglobeandmail.comPharming Group (NASDAQ:PHAR) Lowered to Hold Rating by Wall Street ZenMay 9, 2026 | marketbeat.comPharming Group Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comPharming Group (NASDAQ:PHAR) Issues Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comPharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026May 7, 2026 | markets.businessinsider.comPharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersMay 7, 2026 | markets.businessinsider.comPharming Group N.V. (PHAR) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comPharming Group (NASDAQ:PHAR) Shares Gap Down After Earnings MissMay 7, 2026 | marketbeat.comPharming Group N.V. 2026 Q1 - Results - Earnings Call PresentationMay 7, 2026 | seekingalpha.comPharming earnings in focus: Can rare disease growth offset Q1 dip?May 6, 2026 | investing.comPharming Group (XAMS:PHARM) Q1 2026: Everything You Need To Know Ahead Of EarningsMay 6, 2026 | finance.yahoo.comPharming Group ADR PHGMay 5, 2026 | morningstar.comMHigh Growth Tech Stocks To Watch In May 2026May 5, 2026 | finance.yahoo.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by BrokeragesMay 5, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026Qualcomm's TikTok AI Chip Deal Rewrites the RulesBy Jeffrey Neal Johnson | May 27, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026Amylyx Stock: Why the Full Pipeline Story MattersBy Chris Markoch | May 24, 2026IKT, PHAR, JANX, and ANNX Company DescriptionsAnnexon NASDAQ:ANNX$5.42 +0.05 (+0.93%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$5.90 +0.48 (+8.76%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Inhibikase Therapeutics NASDAQ:IKT$1.75 -0.02 (-1.13%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.77 +0.02 (+1.31%) As of 05/29/2026 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.Janux Therapeutics NASDAQ:JANX$14.59 -0.15 (-1.02%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$14.60 +0.01 (+0.04%) As of 05/29/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Pharming Group NASDAQ:PHAR$12.99 -0.67 (-4.90%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$13.04 +0.05 (+0.38%) As of 05/29/2026 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
